One year ago, The Medicare Negotiation and Competitive Licensing Act was introduced to increase transparency and allow the government to negotiate drug pricing with manufacturers. Recently, the Senate Finance Committee introduced the Prescription Drug Pricing Reduction Act of 2019 to address the high costs of...

The 340B Drug Discount Program has faced numerous attempts at regulatory changes in the last five years; one, in particular, challenged the Orphan Drug rule. The ruling stipulated that manufacturers are not required to provide covered entities orphan drugs under 340B, but a manufacturer may, at...

Despite multiple delays, the Secretary of Health and Human Services, Alex Azar, recently renewed his agencies plan to release regulations for setting 340B drug discount program drug prices. While speaking to the hospital trade group, 340B Health, Azar addressed the provider’s concerns that the multiple delays...